Lookup NU author(s): Dr Peter O'Neill,
Professor Christian Hicks
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Humans are genetically unique. They express diseases and respond to medical treatments differently. Personalised cellular therapies (CTs) are a form of mass customization that require the production and delivery of individualised treatments and services. There has been increasing interest by regenerative medicine firms and regulators in technologies that allow laboratory-based manufacturing processes to be operated in small, scalable, modularized ‘closed’ environments. This paper investigates the influence of product development on the feasibility of mass customization strategies in terms of: i) quality, safety and consistency; and ii) the cost of quality. The research used a multiple case study design with two consortia involved in trials of personalised CTs that use a patient’s own cells (autologous therapies). The findings suggest that clinical development using innovative capital equipment can improve the feasibility of CTs by automating laboratory processes, capturing quality data, and reducing costs. This facilitates the decentralised manufacture of autologous CTs and allows horizontal scaling without sacrificing quality. One consortium reduced the cost of quality and human error, whilst the second also improved product yield. The research highlights the necessity of concurrent product and process development, operations strategy and early multidisciplinary supplier involvement in the clinical development of mass customized CTs.
Author(s): Teng CW, O'Neill P, Hicks C, Sohal A
Editor(s): Missbauer H; Tang O
Publication type: Conference Proceedings (inc. Abstract)
Publication status: Published
Conference Name: Twenty-first International Working Seminar on Production Economics
Year of Conference: 2020
Online publication date: 24/02/2013
Acceptance date: 22/11/2019
Publisher: Universität Innsbruck